SELB Stock Overview
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases.
Selecta Biosciences Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$1.50|
|52 Week High||US$4.51|
|52 Week Low||US$0.65|
|1 Month Change||-28.57%|
|3 Month Change||12.78%|
|1 Year Change||-65.28%|
|3 Year Change||-15.73%|
|5 Year Change||-91.78%|
|Change since IPO||-89.29%|
Recent News & Updates
We Think Selecta Biosciences (NASDAQ:SELB) Can Stay On Top Of Its Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
Selecta: ImmTOR Could Change Autoimmune Disorder Treatment Landscape
Results for both studies from the DISSOLVE phase 3 program, using SEL-212 for the treatment of patients with chronic refractory gout, are expected in Q1 of 2023. Potential to restore immune tolerance and target underlying cause of patients with primary biliary cirrhosis with use of ImmTOR and PDC-E2 co-administration. ImmTOR/ImmTOR-IL holds potential to restore immune tolerance; Potential to allow improvements in multiple types of therapies, including possible re-dosing for gene therapy. Selecta has already established several partnerships for use of ImmTOR/ImmTOR-IL with Sarepta Therapeutics, AskBio, and Takeda Pharmaceutical. Selecta Biosciences, Inc. (SELB) is a great speculative biotech play to look into. Most of its pipeline is in the early stages of development, however, it does have one phase 3 program. This phase 3 programs involves studies known as DISSOLVE I and DISSOLVE II. These studies are using a biologic therapy known as Pegadricase (SEL-212) for the treatment of patients with chronic refractory gout. Why I believe it's worth a look is because has already completed enrollment of the DISSOLVE II study. Topline results are expected in Q1 of 2023. This sets up a huge catalyst to look forward to which could possibly change the scope of the company. The thing to note is that a lot of programs are being developed around the ImmTOR and ImmTOR-IL. In essence, both of these technologies are responsible for inhibiting an immune response observed in autoimmune diseases. The reason? To promote superior safety of therapies and to allow more frequent administration of life saving drugs. It can use its technology platform and apply it to many biologics and gene therapies. For instance, an AAV gene therapy known as SEL-302 for the treatment of patients with Methylmalonic acidemia ((MMA)), is being combined with ImmTOR. A phase 1 study for this patient population is expected to start in Q4 of 2022. Another program of note involves the tolerogenic therapies established in Selecta's pipeline. The goal is to use ImmTOR to be able to target the root cause of patients with primary biliary cholangitis ((PBC)). By adding in ImmTOR, it can suppress a severe immune response observed in the liver when given a particular therapy. Thus, this is how it intends to go after the root cause of PBC. Lastly, there is a potential path forward for a boost in the ImmTOR technology platform. This is to be done with another technology developed by Selecta known as ImmTOR-IL noted above. With ImmTOR-IL, it will be able to expand the scope of Treg (T Regulatory) cells. These Tregs are important in being able to inhibit immune responses to antigens. With so much possibility, plus an expanded pipeline, these are the reasons why I believe it is a great speculative biotech play to look into. ImmTOR Makes Sense For Being Used Against Primary Biliary Cholangitis Primary Biliary Cholangitis is an autoimmune disorder whereby the body mistakenly attacks the bile ducts of the liver. This in turn leads to severe liver damage. Where does ImmTOR come into play here? The goal for Selecta is to use ImmTOR to generate immune tolerance observed in PBC. This is achieved with tolerogenic dendritic cells (DCs) which activate anti-specific regulatory T cells (Tregs) to inhibit such an immune response to the problematic antigens. How is a tolerogenic message sent? What Selecta intends to do is to encapsulate rapamycin and autoantibodies (in the case of targeting PBC it is using autoantigen PDC-E2) in a nanoparticle to allow the dendritic cell to send a tolerogenic message out. The reason to use a nanoparticle for this process is to limit systemic exposure of drug material and to enable self tolerance with ImmTOR. There is, however, a deeper reason on why starting off ImmTOR with encapsulated PDC-E2 against PBC is a smart move. It is because more than 80% of PBC patients have autoantibodies against PDC-E2. If this therapy is done right, then natural self tolerance should be restored and in tandem directly target the root cause of PBC. A potential improvement can also be achieved by adding in ImmTOR-IL. ImmTOR-IL is the use of ImmTOR with a proprietary IL-2 protein agonist. What's the reason for needing ImmTOR-IL? Bottom line, the expansion of antigen-specific Tregs to enhance immune tolerance. It makes sense, the more Tregs in play, the greater the effect of immune tolerance which can be achieved. IND-enabling studies are underway in which ImmTOR-IL is being co-administered with PDC-E2 against PBC to eventually begin a phase 1 human study. Further enhancement for this program is working with its partner Cyrus Biotechnology to develop a next generation IL-2 molecule to be combined with ImmTOR. Such a candidate is expected to be nominated by the end of 2022. The goal is to start off with diseases that have a single pathogenic antigen to focus on, like PBC, then move on to other related indications. Advanced Phase 3 DISSOLVE Program Could Bring Much Needed Proof Of Concept For ImmTOR Selecta is currently undertaking a phase 3 program known as DISSOLVE. This involves DISSOLVE I and DISSOLVE II studies, which are currently ongoing. However, this program is being partnered with Sobi. Selecta received a $10 million milestone payment from Sobi due to completion of enrollment for the DISSOLVE II study. These studies are using SEL-212 to treat patients with chronic refractory gout. Gout is a form of arthritis in which patients have severe pain in their joints in one area. Chronic gout is where such pain and inflammation occurs repeatedly. Not only that, but in other areas of the body as well. Chronic refractory gout remains a huge problem that needs to be dealt with. This is where SEL-212 comes in from Selecta. It is a combination of the company's proprietary pegylated uricase (pegadricase) combined with ImmTOR. Pegadricase was developed to sustain Serum Uric Acid ((SUA)) levels in these patients with chronic refractory gout. ImmTOR as you guessed, to inhibit formation of anti-drug antibodies (ADAs). This is where ImmTOR plays a huge role in that it has the potential to change the landscape in this area if successful. Why is that? Current treatment options like pegloticase cause patients to develop anti-drug antibodies. This is bad because in turn the effectiveness of the treatment is reduced immensely. Thus, Doctors have a need to administer immunomodulators as a co-treatment. On the flip side, ImmTOR may be able to generate an immune tolerance to such autoantibodies. Not only providing safety, but potentially amplifying the effectiveness of the treatment itself. If this is successfully done, it could create a competitive advantage over other approved biologics for chronic refractory gout. The problem with biologics, AAVs and other targeted therapies is that autoantibodies reduce effectiveness of them. If ImmTOR can mitigate the formation of such anti-drug antibodies, then it can have a huge impact in being effective against a cross range of autoimmune disorders. Results from both phase 3 studies from the DISSOLVE program are expected in Q1 of 2023. The point here is that proof of concept will need to be established when this data is read out. That's because it would signify that ImmTOR achieves its primary function of mitigating anti-drug antibodies. This will prove that this technology from Selecta can be applied to other treatment options such as biologics and other gene therapies alike. It has already gone on to advance other wholly owned treatments to prove this point. For starters, SEL-302 is the company's wholly owned gene therapy in combination with ImmTOR for the treatment of patients with Methylmalonic Acidemia ((MMA)). A phase 1 study using this AAV gene therapy with ImmTOR is expected to begin in Q4 of 2022. There are many other early stage programs wholly owned which make use of ImmTOR through the use of biologics, gene therapies or tolerogenic therapies. Multiple Partnerships Could Expand Upon Opportunity with ImmTOR And ImmTOR-IL Platforms The thing is that even though Selecta Biosciences has been able to do well in developing a partnership with Sobi for the use of SEL-212 for the treatment of patients with chronic refractory gout, it has been able to establish additional partnerships based of the ImmTOR technology platform. Such other partnerships established are with Takeda Pharmaceutical (TAK) for lysosomal storage disorders, AskBio for Pompe Disease, and Sarepta Therapeutics (SRPT) for neuromuscular disorders. Speaking of the research license and option agreement with Sarepta for ImmTOR, it was extended. In addition, in June of 2022 it was noted by Sarepta to Selecta that certain pre-clinical milestones were achieved. It will receive a $2 million payment for the extension of the agreement to Q1 of 2023 and a $4 million payment for achieving the preclinical milestones. The receipt of such payments is expected during Q3 of 2022. However, it's important to look at the larger picture here with respect to the ImmTOR technology platform. What drove Sarepta and these other companies to want to partner with Selecta? It's because some challenges plaguing gene therapies and other types of treatments, whereby anti-drug antibodies limit potential/frequency dosing options of said therapies. A major hurdle to gene therapies is the inability to dose more. Why? It all has to do with anti-AAV antibodies which develop with gene therapy. Selecta, along with one of its partners AskBio noted that ImmTOR and ImmTOR-IL were able to potentially address key efficacy and safety challenges found in gene therapy.
|SELB||US Biotechs||US Market|
Return vs Industry: SELB underperformed the US Biotechs industry which returned -30% over the past year.
Return vs Market: SELB underperformed the US Market which returned -23.1% over the past year.
|SELB Average Weekly Movement||13.3%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||15.8%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: SELB is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: SELB's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company’s lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura.
Selecta Biosciences Fundamentals Summary
|SELB fundamental statistics|
Is SELB overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|SELB income statement (TTM)|
|Cost of Revenue||US$78.14m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||0.21|
|Net Profit Margin||24.86%|
How did SELB perform over the long term?See historical performance and comparison
Is SELB undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 3/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for SELB?
Other financial metrics that can be useful for relative valuation.
|What is SELB's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does SELB's PE Ratio compare to its peers?
|SELB PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
SESN Sesen Bio
MREO Mereo BioPharma Group
SELB Selecta Biosciences
Price-To-Earnings vs Peers: SELB is good value based on its Price-To-Earnings Ratio (7.2x) compared to the peer average (8.3x).
Price to Earnings Ratio vs Industry
How does SELB's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Earnings vs Industry: SELB is good value based on its Price-To-Earnings Ratio (7.2x) compared to the US Biotechs industry average (13.9x)
Price to Earnings Ratio vs Fair Ratio
What is SELB's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||7.2x|
|Fair PE Ratio||11.3x|
Price-To-Earnings vs Fair Ratio: SELB is good value based on its Price-To-Earnings Ratio (7.2x) compared to the estimated Fair Price-To-Earnings Ratio (11.3x).
Share Price vs Fair Value
What is the Fair Price of SELB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate SELB's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate SELB's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
How is Selecta Biosciences forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SELB's earnings are forecast to decline over the next 3 years (-43.1% per year).
Earnings vs Market: SELB's earnings are forecast to decline over the next 3 years (-43.1% per year).
High Growth Earnings: SELB's earnings are forecast to decline over the next 3 years.
Revenue vs Market: SELB's revenue is expected to decline over the next 3 years (-24.1% per year).
High Growth Revenue: SELB's revenue is forecast to decline over the next 3 years (-24.1% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SELB's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Selecta Biosciences performed over the past 5 years?
Past Performance Score4/6
Past Performance Score 4/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SELB has high quality earnings.
Growing Profit Margin: SELB became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: SELB has become profitable over the past 5 years, growing earnings by 18.9% per year.
Accelerating Growth: SELB has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: SELB has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).
Return on Equity
High ROE: SELB's Return on Equity (35.4%) is considered high.
Discover strong past performing companies
How is Selecta Biosciences's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: SELB's short term assets ($172.6M) exceed its short term liabilities ($33.8M).
Long Term Liabilities: SELB's short term assets ($172.6M) exceed its long term liabilities ($64.7M).
Debt to Equity History and Analysis
Debt Level: SELB has more cash than its total debt.
Reducing Debt: SELB's debt to equity ratio has increased from 13.4% to 28.9% over the past 5 years.
Debt Coverage: SELB's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: SELB's interest payments on its debt are well covered by EBIT (10.3x coverage).
Discover healthy companies
What is Selecta Biosciences's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SELB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SELB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SELB's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SELB's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as SELB has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Carsten Brunn (51 yo)
Dr. Carsten Brunn, Ph.D. serves as Director at Surface Oncology, Inc. since 2022. He serves as President, Chief Executive Officer and Director of Selecta Biosciences, Inc. since December 1, 2018. Dr. Brunn...
CEO Compensation Analysis
Compensation vs Market: Carsten's total compensation ($USD3.67M) is above average for companies of similar size in the US market ($USD1.68M).
Compensation vs Earnings: Carsten's compensation has been consistent with company performance over the past year.
Experienced Management: SELB's management team is considered experienced (3.5 years average tenure).
Experienced Board: SELB's board of directors are considered experienced (4.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
|13 Jun 22||BuyUS$149,799||Carrie Cox||Individual||130,000||US$1.15|
|09 May 22||BuyUS$38,720||Timothy Barabe||Individual||50,000||US$0.77|
|05 Jan 22||SellUS$41,959||Carsten Brunn||Individual||13,597||US$3.09|
|05 Jan 22||SellUS$10,541||Lloyd Johnston||Individual||3,416||US$3.09|
|05 Jan 22||SellUS$10,541||Takashi Kishimoto||Individual||3,416||US$3.09|
|05 Jan 22||SellUS$9,955||Peter Traber||Individual||3,226||US$3.09|
|15 Dec 21||BuyUS$631,099||Timothy Springer||Individual||211,190||US$2.99|
|13 Dec 21||BuyUS$11,687,810||Timothy Springer||Individual||3,821,273||US$3.06|
|10 Dec 21||SellUS$51,363||Carsten Brunn||Individual||17,196||US$2.99|
|10 Dec 21||SellUS$13,053||Lloyd Johnston||Individual||4,370||US$2.99|
|10 Dec 21||SellUS$13,053||Takashi Kishimoto||Individual||4,370||US$2.99|
|10 Dec 21||SellUS$12,196||Peter Traber||Individual||4,083||US$2.99|
|03 Dec 21||BuyUS$50,664||Carrie Cox||Individual||17,200||US$2.95|
|02 Dec 21||BuyUS$20,723||Nishan DeSilva||Individual||7,000||US$2.96|
|02 Dec 21||BuyUS$15,127||Kevin Tan||Individual||5,000||US$3.03|
|13 Oct 21||SellUS$67,224||Carsten Brunn||Individual||15,313||US$4.39|
|13 Oct 21||SellUS$17,086||Lloyd Johnston||Individual||3,892||US$4.39|
|13 Oct 21||SellUS$17,086||Takashi Kishimoto||Individual||3,892||US$4.39|
|13 Oct 21||SellUS$15,962||Peter Traber||Individual||3,636||US$4.39|
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 32.7%.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Selecta Biosciences, Inc.'s employee growth, exchange listings and data sources
- Name: Selecta Biosciences, Inc.
- Ticker: SELB
- Exchange: NasdaqGM
- Founded: 2007
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$229.070m
- Shares outstanding: 152.71m
- Website: https://selectabio.com
Number of Employees
- Selecta Biosciences, Inc.
- 65 Grove Street
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|SELB||NasdaqGM (Nasdaq Global Market)||Yes||Common Stock||US||USD||Jun 2016|
|1S7||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jun 2016|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/09/24 00:00|
|End of Day Share Price||2022/09/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.